Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Orexin (Hypocretin) peptide icon, one bubble per amino acidOrexin (Hypocretin)33 residuesQPLPDCCRQKTCSCRLYELLHGAGNHAAGILTLEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Orexin (Hypocretin)

SleepResearch
30 min half-life·Injection/Nasal·4w on / 2w off

Also known as: Hypocretin-1, OX-A, Hcrt-1

Only 22 published human subjects. That's the entire evidence base for intranasal Orexin-A, a 33-amino-acid neuropeptide that controls whether you stay awake or fall asleep. The orexin system is so validated that two FDA-approved drugs (suvorexant, lemborexant) block it to treat insomnia. But using the native peptide itself? That's still deep research territory. Narcolepsy type 1 researchers and sleep neuroscience investigators are the primary audience here, drawn by a compelling biological target that the pharmaceutical industry chose to pursue with small molecules instead.

What Is Orexin (Hypocretin)?

Two labs discovered it in the same year. In 1998, Sakurai's group called it orexin; de Lecea's group named it hypocretin. Both were right about its importance. Orexin-A (Hypocretin-1) is a 33-amino-acid neuropeptide produced by roughly 70,000 neurons in the lateral hypothalamus. Those neurons project to every major arousal center in the brain.

When those neurons die, narcolepsy type 1 results. Cerebrospinal fluid Orexin-A below 110 pg/mL confirms the diagnosis. The FDA validated the orexin system as a drug target by approving suvorexant and lemborexant, both dual orexin receptor antagonists for insomnia.

The native peptide is a different story. Only two published human studies exist using exogenous intranasal Orexin-A: Barateau's 2013 narcolepsy trial (n=12)[1] showed fewer wake-REM transitions at 435 nmol, and Trinder's 2022 pilot (n=10)[2] confirmed significant sympathetic nerve activation at 500 nmol in healthy men. Both used ~1,550-1,780 mcg intranasally. Community protocols at 10-50 mcg sit 30-178x below those doses and have no documented CNS efficacy.

The research field has moved on to small-molecule OX2R agonists like oveporexton, which received FDA Priority Review in February 2026. The native peptide stays a research tool, not a therapeutic candidate.

How Orexin (Hypocretin) Works

Orexin-A and Orexin-B bind two G-protein-coupled receptors, OX1R and OX2R. OX1R couples to Gq proteins, activating phospholipase C and triggering intracellular calcium release through inositol trisphosphate signaling. OX2R couples to both Gq and Gi/Go pathways, giving it a broader modulatory profile. OX1R has a tenfold preference for Orexin-A over Orexin-B; OX2R binds both peptides with similar affinity.

OX2R drives most of the wakefulness effect. The flip-flop model of sleep-wake switching depends on orexin neurons as the stabilizer. These neurons collect inputs from the circadian clock (suprachiasmatic nucleus), sleep pressure signals (adenosine buildup), and metabolic sensors (leptin, ghrelin, glucose). They then fire excitatory projections across all major arousal systems: locus coeruleus for norepinephrine, tuberomammillary nucleus for histamine, dorsal raphe for serotonin, ventral tegmental area for dopamine, and basal forebrain for acetylcholine.

The appetite connection runs through OX1R projections to the arcuate nucleus. Reward-related effects come from OX1R-dense projections to the ventral tegmental area, where orexin boosts dopaminergic signaling. Cardiovascular sympathoexcitation traces to projections reaching the rostral ventrolateral medulla and spinal cord intermediolateral cell column.

Orexin (Hypocretin) Benefits

  • Orexin-A benefits center on wakefulness regulation and arousal system stabilization.
  • Reduced wake-to-REM transitions in narcolepsy type 1 patients at 435 nmol intranasally, with improved divided attention scores (n=12, single-dose crossover)[1].
  • Intranasal Orexin-A reversed cognitive deficits in sleep-deprived rhesus monkeys, restoring short-term memory performance to rested baseline (Deadwyler 2007)[3].
  • PET imaging confirmed CNS penetration via the olfactory-trigeminal pathway in primate models after intranasal delivery (ACS Chem Neurosci, 2018).
  • Orexin-A is roughly 6x more stable than Orexin-B in plasma (~30-minute vs ~5-minute half-life), making it the only viable peripheral form for research applications.
  • The orexin system is one of the most validated drug targets in sleep medicine; two FDA-approved insomnia drugs (suvorexant, lemborexant) block the same receptors that Orexin-A activates.

Orexin (Hypocretin): Science vs Community Consensus

Divergent
Scientific Evidence
Weak
Based on 7 key studies·Research only

Intranasal Orexin-A reduces wake-REM transitions in narcolepsy patients and produces significant sympathoexcitation in healthy humans.

Dosing studied: ~1,549–1,781 mcg intranasally (435–500 nmol): only doses tested in humans with CNS endpoints
Read the evidence (key study, limitations)

Both human studies used ~1,549–1,781 mcg (435–500 nmol) intranasally. No published human data exists below ~1,500 mcg for CNS wakefulness effects.

Key Study

PMID 24406723 (Barateau 2013, n=12 narcolepsy type 1, 435 nmol IN, fewer wake-REM transitions, improved divided attention); PMID 35044844 (Trinder 2022, n=10 healthy lean males, 500 nmol IN, significant MSNA/sympathoactivation)

Limitations

Only 2 published human studies with exogenous intranasal orexin-A peptide (n=10–14 each, single-dose crossover design). No multi-week dosing protocol in humans. SC route has no demonstrated CNS efficacy due to BBB impermeability of the 33-AA peptide. No approved human therapeutic protocol exists for the native peptide. Research field has pivoted to small-molecule OX2R agonists.

Community Experience
Weak
3.0/5
Based on fewer than 50 dedicated Reddit threads

Extremely thin adoption.

Community dosing: 10–50 mcg SC or intranasal (community-reported, almost certainly sub-pharmacological)
Read the reports (what users report 3, common issues 5)

High conceptual interest but minimal documented self-use. Fewer than 50 dedicated Reddit threads. Community doses (10–50 mcg SC or intranasal) are 30–178× below published human CNS-active doses and likely produce no meaningful wakefulness effect.

What users report (3)
  • Conceptual interest as direct orexin replacement for narcolepsy before OX2R agonist drugs become available
  • Rapid-onset alertness in animal/primate models at pharmacological doses motivates research interest
  • Wake architecture improvement theorized from sleep-deprivation primate data
Common issues (5)
  • No established human dose: community doses (10–50 mcg) are almost certainly sub-pharmacological with no documented CNS efficacy
  • Prohibitive cost at pharmacologically relevant doses: one dose at ~1,750 mcg consumes ~35% of a 5mg vial (~$90 consumer price)
  • Orexin-B is practically unusable peripherally (~5-min half-life, no CNS penetration): Orexin-A is the only viable peripheral form
  • Significant cardiovascular sympathoexcitation at published human doses warrants BP/HR monitoring
  • Disulfide bond fragility makes reconstitution errors (shaking) a real quality-degradation risk
Science & Community Diverge

Science requires ~1,500–1,800 mcg intranasally for any documented CNS wakefulness effect in humans. Community protocols use 10–50 mcg: 30–178× below published human doses. Community doses may be tolerable but have no evidence of efficacy. Research field has moved to small-molecule OX2R agonists (oveporexton FDA Priority Review Feb 2026), making the native peptide increasingly niche.

Orexin (Hypocretin) Dosage Guide

SpeculativeResearch peptide; clinical orexin agonists differ structurally and in dose
LevelDose / InjectionFrequency
Beginner10 mcg
DailyTrack
Moderate30 mcg
DailyTrack
Aggressive50 mcg
2x DailyTrack
Note:

Orexin-A comes as a lyophilized powder. Reconstitute a 1 mg vial with 2 mL bacteriostatic water. That gives you 500 mcg/mL, or 5 mcg per unit on a 100-unit insulin syringe. At the community starting dose of 10 mcg, that's 2 units drawn into a syringe and loaded into a nasal spray device. At 30 mcg, draw 6 units; at 50 mcg, draw 10 units.

The reconstitution step matters more here than with most peptides. Orexin-A has two disulfide bonds and an N-terminal pyroglutamyl modification. Shaking the vial can break disulfide connectivity and destroy bioactivity. Add bacteriostatic water slowly down the vial wall. Swirl gently. Never vortex.

Morning dosing only. This peptide activates every arousal circuit in the brain. Afternoon or evening use at any effective dose is asking for insomnia.

One more thing worth knowing: community doses (10-50 mcg) are 30-178x below the only human doses that showed CNS effects. Published human studies used ~1,550-1,780 mcg intranasally. At that dose, a 5 mg vial gives you roughly 2.8 doses at ~$32 each from consumer sources.

Cycling Protocol

On Period
4 weeks
Off Period
2 weeks

Cycling recommendations are extrapolated from general neuropeptide research protocols. Due to receptor desensitization potential at OX1R and OX2R, periodic off-periods are advisable. No human clinical cycling data exists for the native peptides.

Calculate your Orexin (Hypocretin) dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

Orexin (Hypocretin) Protocols by Goal

advancedClinical TrialUndefined: no multi-week human protocol published; both studies used acute single-dose crossover design
Acute intranasal administration (published human dose)
Wk Single-dose crossover design (no multi-week protocol published)
~1,549–1,781 mcg (435–500 nmol) · Once AM (study design: acute single dose) · intranasal

Expected: Reduced wake-REM transitions and improved divided attention in narcolepsy (PMID 24406723). Significant MSNA increase and sympathoexcitation in healthy subjects (PMID 35044844): both wakefulness benefit and cardiovascular adverse effect are expected.

Monitor: BP and HR monitoring required at this dose range. Significant sympathoexcitation demonstrated in healthy lean males. Contraindicated in hypertension, cardiovascular disease, or arrhythmia.

How to Use Orexin (Hypocretin)

  1. 1
    Pull 2 mL of bacteriostatic water into a syringe

    Inject slowly down the inside wall of a 1 mg Orexin-A lyophilized vial. Do not shake. Swirl gently until the powder dissolves completely. This gives a concentration of 500 mcg/mL (5 mcg per unit on a standard 100-unit insulin syringe).

  2. 2
    Draw your target dose: 10 mcg = 2 units

    30 mcg = 6 units. 50 mcg = 10 units. Use a 29-31 gauge insulin syringe for measurement accuracy.

  3. 3
    Step 3

    For intranasal delivery (the preferred research route): transfer the measured dose into a nasal atomizer or mucosal atomization device. Tilt your head slightly forward. Spray into one nostril while gently inhaling. Alternate nostrils between doses.

  4. 4
    Step 4

    For subcutaneous injection (peripheral effects only, no expected CNS penetration): inject into the abdominal area. Rotate sites. Note that the full 33-amino-acid peptide does not meaningfully cross the blood-brain barrier from systemic circulation.

  5. 5
    Dose in the morning only

    Orexin drives wakefulness; afternoon or evening dosing at any CNS-active level risks insomnia.

  6. 6
    Step 6

    Check blood pressure and heart rate before your first dose and 20-30 minutes after. Any systolic rise above 20 mmHg or sustained heart rate above 100 bpm warrants dose reduction.

  7. 7
    Store the reconstituted vial at 2-8 degrees C

    Use within 14 days. Do not freeze reconstituted solution. Protect from light.

Alternative Routes

Intranasal

Published human doses ~1,549–1,781 mcg (435–500 nmol). Community conservative: 10–50 mcg (likely sub-pharmacological).

CNS delivery confirmed via olfactory-trigeminal pathway in primates (PET imaging, ACS Chem Neurosci 2018). Requires intranasal delivery device. Consumer nasal spray adapters vary in droplet size and delivery efficiency, affecting CNS bioavailability at a given dose.

Subcutaneous injection

No established dose. The full 33-AA peptide is too large for significant BBB crossing from systemic circulation.

SC may produce peripheral orexin receptor effects (appetite stimulation, autonomic tone) but will not generate CNS wakefulness or arousal. Community 10–50 mcg SC has no documented CNS efficacy. Not appropriate as the primary route for any wakefulness indication.

Intracerebroventricular (ICV)

Nanomolar quantities sufficient due to direct CNS delivery: not relevant to peripheral dosing contexts

ICV is the standard delivery method in rodent orexin circuit research. Not applicable to self-administration.

Mixing your own vial? Use the Orexin (Hypocretin) reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

Orexin (Hypocretin) Stacking Protocols

Works With

Avoid

Suvorexant (Belsomra) / Lemborexant (Dayvigo)

Direct pharmacological opposition. DORAs block OX1R/OX2R: the same receptors exogenous Orexin-A activates. Co-administration produces mutual antagonism and negates both agents.

Do not combine
Modafinil / Armodafinil

Additive sympathoexcitation. Modafinil activates endogenous orexin neurons upstream; exogenous Orexin-A acts directly on OX1R/OX2R downstream. Combined arousal and cardiovascular strain. No interaction data; caution warranted.

Amphetamines / ADHD stimulants (amphetamine, lisdexamfetamine)

Additive sympathoexcitation and CV strain. Significant MSNA increase already demonstrated with Orexin-A alone at published doses (PMID 35044844). Stimulant combination poses meaningful cardiovascular risk.

Do not combine
Beta-blockers (propranolol, metoprolol)

May mask orexin-mediated cardiovascular sympathoexcitation signal, potentially obscuring a dose-limiting adverse effect marker.

Estimated Cost

Generic / Research
~$18–$27/mg consumer-grade: 5mg vial ~$89.95; 5mg nasal spray ~$133.09
Brand Price
Academic/lab-grade reagent pricing: roughly $151 per 100 mcg to $506 per mg (reference/research grade, not for self-use)

Pricing updated 2026-04-09

Orexin (Hypocretin) Side Effects

Significant sympathetic nerve activation is the primary safety concern. Trinder's 2022 pilot study (n=10 healthy lean males)[2] showed marked muscle sympathetic nerve activity increases at 500 nmol intranasally. That translates to raised heart rate, blood pressure rises, and cardiovascular strain at pharmacologically active doses. This is not a theoretical risk; it was measured directly in healthy subjects.

The human side-effect profile beyond those 22 total subjects is unknown. Preclinical data fills some gaps but carries the usual species-translation uncertainty.

In animal models, higher-dose intranasal Orexin-A produced increased locomotor activity, tachycardia, and transient blood pressure elevation. Central administration at supraphysiological doses triggered anxiety-like behavior and stress-axis activation through corticotropin-releasing hormone signaling. These findings are consistent with orexin's known role as a sympathoexcitatory neuropeptide.

Appetite stimulation is a predictable pharmacological effect. Orexin was literally named for appetite (Greek "orexis" = appetite). If you're using this peptide and noticing increased hunger, that's the drug doing what the molecule does.

Insomnia from mistimed dosing is a real risk at any CNS-active dose. Orexin neurons are maximally active during waking hours. Any dose given after noon that actually reaches the brain could delay sleep onset or fragment sleep architecture.

Injection-site irritation has been reported in animal subcutaneous studies. Intranasal administration carries the usual local effects: nasal irritation, mild burning, and congestion.

Orexin neurons interact with monoaminergic, cholinergic, and histaminergic arousal systems. The potential for excessive arousal when combining with stimulants (modafinil, amphetamines) or other sympathoexcitatory agents is not a small concern.

Contraindications include uncontrolled hypertension, cardiovascular disease, arrhythmia, severe anxiety disorders (orexin may activate the HPA axis), concurrent orexin receptor antagonists (pharmacological opposition), and pregnancy or breastfeeding (zero safety data). Stop use immediately if blood pressure rises more than 20 mmHg systolic post-dose, heart rate exceeds 100 bpm sustained, or you experience chest tightness, panic symptoms, or significant anxiety.

Common Issues & Solutions

Sub-pharmacological dosing (10–50 mcg): If no wakefulness effect is observed, the dose is almost certainly below the CNS-active threshold: not evidence of individual non-response to orexin biology. Published human floor is ~1,549 mcg intranasally.

Using Orexin-B instead of Orexin-A: Orexin-B is a linear 28-AA peptide with ~5-min half-life and negligible CNS penetration from peripheral routes. It is functionally inert for non-ICV peripheral administration. Always confirm the compound is Orexin-A (Hypocretin-1).

Reconstitution error (shaking): Orexin-A has two disulfide bonds and N-terminal pyroglutamyl modification that are shear-sensitive. Never shake the vial. Add bacteriostatic water slowly down the vial wall and gently swirl only.

Evening dosing causing insomnia: Orexin neurons are maximally active during waking hours and drive sleep-state resistance. Any CNS-penetrant dose given after noon risks delayed sleep onset or fragmented sleep. Morning-only dosing is essential.

Cardiovascular symptoms at higher doses: At pharmacologically relevant doses (~1,500+ mcg), significant MSNA increase is expected [2]. Tachycardia, elevated BP, or anxiety warrant dose reduction or discontinuation. Pre-existing hypertension, cardiovascular disease, or arrhythmia is a contraindication.

Ask AI about this page

Ask AI for a second opinion on Orexin (Hypocretin) dosing and side effects

Contraindications

  • Known hypersensitivity to orexin peptides or excipients
  • Uncontrolled hypertension due to sympathoexcitatory effects
  • Severe anxiety disorders (orexin may exacerbate HPA axis activation)
  • Concurrent use of orexin receptor antagonists (suvorexant, lemborexant)
  • Pregnancy or breastfeeding (no safety data available)

Drug Interactions

  • Suvorexant and lemborexant (dual orexin receptor antagonists: pharmacological opposition)
  • Stimulants such as modafinil or amphetamines (additive arousal effects)
  • Sedative-hypnotics and benzodiazepines (opposing pharmacological effects)
  • Beta-blockers (may attenuate orexin-mediated cardiovascular responses)
  • CRH receptor antagonists (potential interaction via stress-axis modulation)

Product Quality

Recommended Monitoring

TestWhenTarget
Blood pressure (seated, resting)Before first dose; 20–30 min after dose during first week at any new dose level<130/85 mmHg pre-dose; >20 mmHg systolic increase post-dose warrants dose reduction
Resting heart rateAlongside BP monitoring after each dose in first week55–80 bpm pre-dose; sustained >100 bpm post-dose warrants dose reduction
Subjective wakefulness / Epworth Sleepiness Scale (ESS)Baseline and weekly throughout protocolESS score reduction ≥3 points from baseline indicates meaningful wakefulness improvement
Blood pressure (seated, resting)

Significant MSNA and sympathoexcitation demonstrated in healthy humans at published doses (PMID 35044844). Baseline hypertension, cardiovascular disease, or arrhythmia are contraindications.

Resting heart rate

Orexin sympathoexcitation includes cardiac acceleration. Tachycardia is an early cardiovascular signal.

Subjective wakefulness / Epworth Sleepiness Scale (ESS)

Validated self-reported measure of daytime sleepiness. ESS reduction would be the primary efficacy endpoint. In narcolepsy: CSF orexin-A <110 pg/mL is a clinical diagnostic marker but not accessible for self-monitoring.

Orexin (Hypocretin) Before and After

Week 1

Baseline assessment; initial tolerability evaluation in research protocols

Weeks 2-3

Observable changes in wakefulness duration and sleep-wake consolidation in animal models

Weeks 3-4

Peak effects on alertness, locomotor activity, and feeding behavior noted in preclinical studies

Weeks 4-6

Assessment of sustained efficacy and potential receptor desensitization; cycling off-period may begin

What to Expect

Day 1, first dose: At published human doses (~1,550-1,780 mcg intranasal), expect rapid sympathetic activation within 15-30 minutes. Plasma tmax is roughly 15-30 minutes based on primate PK data, and the half-life is about 30 minutes, so acute effects are transient. In the Barateau narcolepsy study, wakefulness improvement appeared at this timepoint; in Trinder's healthy-subject pilot, sympathoexcitation was the dominant signal. At community doses (10-50 mcg), most users report nothing perceptible, consistent with the sub-pharmacological dose range. Nasal irritation and transient raised heart rate or blood pressure are the main acute side effects at higher doses.

Weeks 1-2: No multi-week human data exists at any dose. Animal models showed sustained wakefulness consolidation with repeated dosing, but the receptor desensitization timeline at OX1R and OX2R in humans is unknown. Most community members report dropping the protocol by week 2 because nothing is happening at 10-50 mcg doses.

Weeks 3-4: This is the theoretical peak protocol window, though no human data defines it. The community standard of 4 weeks on, 2 weeks off is borrowed from other neuropeptide cycling conventions. It is not based on any orexin-specific evidence.

Off-cycle (weeks 5-6): The receptor recovery period. GPCR upregulation during the agonist-free interval is the theoretical rationale. No withdrawal or discontinuation effects have been reported at community doses, which makes sense if the doses never engaged receptors meaningfully in the first place.

Detailed Timeline: Science vs Community

Day 1: first dose
Science

At published human doses (~1,550–1,780 mcg IN): rapid sympathetic activation within 15–30 min. Plasma tmax ~15–30 min (primate PK). Half-life ~30 min: acute effects are transient. Wakefulness improvement in narcolepsy patients; sympathoexcitation in healthy subjects.

Community

At community doses (10–50 mcg): most users report no perceptible effect: consistent with sub-pharmacological dose range. Occasional placebo-level mild alertness reported.

Week 1–2
Science

No multi-week human data. Animal models show sustained wakefulness consolidation with repeat dosing. Receptor desensitization timeline at OX1R/OX2R unknown in humans.

Community

Most community members report abandoning protocol by week 2 due to perceived lack of effect at sub-pharmacological doses.

Week 3–4
Science

No human multi-week data. Theoretical benefit window before receptor desensitization; no data to define this timeline for the native peptide.

Community

4 weeks on / 2 weeks off is the community standard, extrapolated from other neuropeptide protocols: not from any orexin-specific data.

Off-cycle (weeks 5–6)
Science

No human data. GPCR upregulation expected during agonist-free period: the theoretical basis for cycling.

Community

No withdrawal or discontinuation effects reported at community doses, consistent with sub-pharmacological (likely non-receptor-engaging) use.

Pharmacokinetics

Half-Life
30min
Bioavailability
SC: limited CNS penetration; Intranasal: improved CNS delivery demonstrated in primates
Tmax
~15-30 minutes (intranasal, primate data)
Data Confidence
low

Source: Kastin AJ, Akerstrom V. Orexin A but not orexin B rapidly enters brain from blood by simple diffusion. J Pharmacol Exp Ther. 1999;289(1):219-223. PMID: 10087007

Pharmacokinetics: Active Dose Over Time

t½ = ~30 minutes (Orexin-A); ~5 minutes (Orexin-B)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
33
Sequence
QPLPDCCRQKTCSCRLYELLHGAGNHAAGILTL
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: 205640-90-0 (Orexin-A, human)PubChem 56842143 (opens in a new tab)

Who Should Consider Orexin (Hypocretin)

  • Researchers studying narcolepsy and sleep disorders
  • Neuroscientists investigating arousal and wake circuits
  • Individuals with excessive daytime sleepiness (research context)
  • Investigators exploring appetite and metabolic regulation
  • Preclinical researchers studying reward and addiction pathways

Related Peptides

What Changed for Orexin (Hypocretin)

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 8, 20267 Citations

References

  1. [1]The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy (Weinhold et al., Behav Brain Res 2014) (opens in a new tab)(n=12)PubMed (opens in a new tab)PubMed
  2. [2]Intranasal orexin A modulates sympathetic vascular tone: a pilot study in healthy male humans (Meusel et al., J Neurophysiol 2022) (opens in a new tab)(n=12)PubMed (opens in a new tab)PubMed
  3. [3]Nasal administration of orexin-A (hypocretin-1) reverses the sleep-deprivation deficit in non-human primates (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Up to 24 months at -20°C
After Reconstitution
Use within 14 days when stored at 2-8°C
Temperature
-20°C for long-term; 2-8°C after reconstitution

Frequently Asked Questions

A PET imaging study (ACS Chem Neurosci, 2018) showed detectable CNS penetration in primate models via the olfactory-trigeminal pathway. SubQ Orexin-A barely crosses the blood-brain barrier because the full 33-amino-acid peptide is too large. Intranasal is the only peripheral route with evidence of CNS delivery.

The native peptides are too unstable and too expensive to synthesize at scale. Pharma companies focused on small-molecule OX2R agonists instead (like TAK-994 for narcolepsy). The peptide stays a research tool while drug-like small molecules move through trials.

One narcolepsy study (PMID 24406723, n=12) showed reduced wake-REM transitions and improved attention at roughly 435 nmol intranasally. It's the most directly relevant human evidence, but it's a very small single-center study.

Orexin-A is what you want. It has two disulfide bonds and an N-terminal modification giving it about a 30-minute plasma half-life. Orexin-B is a linear peptide with roughly a 5-minute functional half-life and essentially zero peripheral-to-CNS penetration, making it impractical for anything except direct brain injection.

No interaction studies exist. The concern is additive cardiovascular strain: a 2022 human pilot showed significant sympathetic nerve activity increases even in healthy lean men at 500 nmol. Stacking with modafinil (which also hits norepinephrine and orexin systems) warrants real caution.